2022-07-05-世界卫生组织-Immunization_Tunisia_2022_country_profile_20页_378kb

Summary of WHO and UNICEF Immunization Coverage Estimates in Tunisia (2021 Revision)

Overview

The report provides WHO and UNICEF's estimates of national immunization coverage for Tunisia, focusing on key vaccines such as BCG, DTP, polio, and hepatitis B. Estimates are based on empirical data from national reports, administrative records, and surveys, and aim to reflect routine immunization coverage for children. Coverage is assessed for various doses, including first, second, and third doses, with grades of confidence (GoC) indicating the reliability of the estimates.

Key Vaccines and Coverage Trends

• BCG: Coverage remains high, averaging 94-98% over the period (2010-2021).
• DTP1 and DTP3: Excellent coverage, typically above 90%, with some fluctuations due to data challenges.
• Polio-related (Pol3): Consistently high, around 90-98%, with no indication of decline.
• Hepatitis B (HepBB and HepB3): Birth dose coverage is high (e.g., 80-85%), but third-dose coverage is moderate to high (90-98%), with some variability.
• Measles-containing vaccines (MCV1, MCV2): Average 90-98% coverage, with high confidence in estimates for MCV1.
• Inactivated Polio Vaccine (IPV1): Introduction in 2015; coverage is lower in early years (e.g., 60-80%) but improves to 90-98% by 2020-2021.
• Hib3 and PCV3: Coverage is high for Hib after introduction in 2011 (e.g., 90-98%), and recent for PCV3 (introduced post-2018).
• Rubella-containing (RCV1): Estimates derived from MCV, uniformly between 95-98%.
• RotaC: Coverage is mostly above 90%, but data quality varies.

Data Sources and Methods

Estimates rely on reported national coverage data, administrative records, and surveys. WHO and UNICEF use a grade of confidence methodology based on data sources, survey evidence, and expert review. Administrative data may underestimate coverage due to private sector doses not being fully captured. Many estimates have high confidence (GoC R+ or S+) but some are challenged (GoC D- or S-) due to data biases or inconsistencies, such as recall bias in surveys.

General Notes

Most indicators show stable or improving coverage, particularly for foundational vaccines like BCG and DTP. However, newer vaccines like IPV and PCV have shown improvement. Operations are pending review to address systematic issues and private sector contribution, with next revision available July 15, 2023. These estimates should be used cautiously, considering data quality and potential overestimation risks.